Biologic Selection for Rheumatoid Arthritis in Pregnancy
Nine weeks into a wanted pregnancy, her methotrexate has to stop immediately, but which biologic replaces it turns on a placental transport mechanism most patients never have reason to think about.
Amara J., a 33-year-old woman, teaches high school chemistry and found out three weeks ago that she is nine weeks pregnant with her second child, news she and her husband had been hoping for since deciding last year to try again. Her rheumatoid arthritis, six years old, has been well controlled for the past two years on adalimumab combined with low-dose methotrexate — a combination that now has to change immediately regardless of which biologic question gets decided, since methotrexate is a well-established teratogen with no acceptable use in pregnancy at any dose.
The biologic decision is less settled. Certolizumab pegol is structurally different from other TNF inhibitors in a way that matters specifically here: it is a PEGylated antibody fragment lacking the Fc region that other TNF inhibitors use to hitch a ride across the placenta via the neonatal Fc receptor, a transport pathway that becomes increasingly active as pregnancy progresses. The CRIB study, designed specifically to measure this, found certolizumab present at negligible-to-undetectable levels in cord blood and infant serum across all three trimesters, a cleaner profile than any other TNF inhibitor has demonstrated. Adalimumab, by contrast, is actively transported across the placenta in increasing amounts through the second and third trimesters — a real, measured phenomenon, though one the ACR's own 2020 reproductive health guideline still treats as compatible with continuing adalimumab through pregnancy, generally with attention to the timing of the last dose relative to delivery. That timing detail exists for a concrete reason: an infant born with meaningful circulating TNF inhibitor from a third-trimester maternal dose should not receive a live vaccine, such as the rotavirus vaccine on the standard two-month schedule, until the drug has cleared — a precaution that traces back to a well-documented case of a fatal disseminated BCG infection in an infant exposed to infliximab late in pregnancy and then vaccinated on the usual newborn schedule. She is still early enough — nine weeks — that any switch would happen well before the placental transport question becomes most active, though a first-trimester switch is not itself a risk-free maneuver in a disease that flares when treatment changes.
Choosing the biologic for the pregnancy ahead
I'd switch her to certolizumab pegol now, while she's still early. It's structurally different from other TNF inhibitors — it lacks the Fc region that lets antibodies hitch a ride across the placenta via the neonatal Fc receptor, a pathway that gets more active as pregnancy goes on. The CRIB study measured this directly and found certolizumab at negligible-to-undetectable levels in cord blood across all three trimesters — the cleanest transfer profile of any TNF inhibitor we have data on.
The transfer data are real, and I'm not disputing the mechanism. But adalimumab is an accepted option through pregnancy under the ACR's own 2020 reproductive health guideline, and she's been in remission on it for two years. Switching medication, even early, isn't a costless maneuver in a disease that flares when treatment changes — and a flare in early pregnancy isn't something either of us wants to manage on top of everything else happening in the first trimester.
If she were further along, I'd agree the placental transport difference matters enough to justify the switch regardless of that risk — the transport pathway is most active exactly when a switch would be hardest to manage safely. But she's nine weeks. A switch now happens well before that transport question becomes most active, which is precisely the window where switching costs the least and buys the most.
Put that way, I'd support switching to certolizumab now rather than waiting — I just wanted the flare risk named directly rather than assumed away because the timing happens to be favorable.
Agreed: switch to certolizumab pegol now, in the first trimester, with close monitoring for a flare during the transition and folic acid continued at pregnancy-appropriate dosing.
Not agreed, though narrowed considerably during the conversation: whether the switch was clinically necessary or a reasonable precaution given a favorable window. The rheumatologist's final position was that the timing made the switch worth doing, not that continuing adalimumab would have been unsafe — a real difference in framing from the maternal-fetal medicine specialist's view that the transport data alone justified the change.